<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02099747</url>
  </required_header>
  <id_info>
    <org_study_id>EBMT-RACE</org_study_id>
    <secondary_id>2014-000363-40</secondary_id>
    <nct_id>NCT02099747</nct_id>
  </id_info>
  <brief_title>hATG+CsA vs hATG+CsA+Eltrombopag for SAA</brief_title>
  <acronym>RACE</acronym>
  <official_title>A Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Society for Blood and Marrow Transplantation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Society for Blood and Marrow Transplantation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The null hypothesis of no difference in CR% at 3 months between the arms will be tested&#xD;
      against the alternative of a difference in CR% at an alpha level of .05 by assessing the odds&#xD;
      ratio for arm yielded by this model.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a superiority trial aiming to increase the 3 month complete response rate. The sample&#xD;
      size is calculated on the hypothesis that the experimental treatment will increase the 3&#xD;
      months response rate up to 21% (by 3 folds, based on the 7% reported in Scheinberg et al&#xD;
      [17]). Under these assumptions, the sample size to reject the null hypothesis is n=96&#xD;
      patients for each treatment arm, increased by 4% for possibly not evaluable patients (total&#xD;
      number of 200 patients, 100 each treatment arm). Statistical design for sample size&#xD;
      calculation: increase from 7% (control arm) to 21% (investigational arm) in 3 month complete&#xD;
      response rate (two-sided binomial test); alpha-error 0.05; power 0.8.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">December 2020</completion_date>
  <primary_completion_date type="Actual">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CR rate</measure>
    <time_frame>3 months</time_frame>
    <description>The primary objective of this trial is to investigate whether Eltrombopag added to standard immunosuppressive treatment increases the rate of early (at three months) complete response in untreated AA patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to best heamatological response</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heamatological Response at 6, 12, 18 and 24 months</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of response</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse rate</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidences of clonal evolution</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of PNH population occurrence and clinical hemolytic PNH occurrence</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of discontinuation of immunosuppressive therapy</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of CsA-independent hematological response at 24 months</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for transfusions and number of transfusions required from treatment</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for any supportive care</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of number of SAEs between the two arms</measure>
    <time_frame>2 year</time_frame>
    <description>To look for the safety and tolerability of the investigational treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Severe Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>hATG + CsA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control Arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hATG + CsA + Eltrombopag</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hATG</intervention_name>
    <arm_group_label>hATG + CsA</arm_group_label>
    <arm_group_label>hATG + CsA + Eltrombopag</arm_group_label>
    <other_name>ATGAM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CsA</intervention_name>
    <arm_group_label>hATG + CsA</arm_group_label>
    <arm_group_label>hATG + CsA + Eltrombopag</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltrombopag</intervention_name>
    <arm_group_label>hATG + CsA + Eltrombopag</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of severe or very severe aplastic anemia, defined by [29]:&#xD;
&#xD;
               -  At least two of the following:&#xD;
&#xD;
                    -  Absolute neutrophil counts &lt;0.5 x 109/L (severe) or &lt;0.2 x 109/L (very&#xD;
                       severe)&#xD;
&#xD;
                    -  Platelet counts &lt;20 x 109/L&#xD;
&#xD;
                    -  Reticulocyte counts &lt;60 x 109/L&#xD;
&#xD;
               -  Hypocellular bone marrow (&lt;30% cellularity), without evidences of fibrosis or&#xD;
                  malignant cells&#xD;
&#xD;
          2. Male or female age &gt; 14 years;&#xD;
&#xD;
          3. Written informed consent&#xD;
&#xD;
          4. Willing and able to comply with all of the requirements and visits in the protocol&#xD;
&#xD;
          5. Understands that they can be randomised to either treatment arm&#xD;
&#xD;
          6. Negative pregnancy test for women of child bearing age&#xD;
&#xD;
          7. Written acceptance to use contraception (hormonal or barrier method of birth control;&#xD;
             abstinence) for the entire duration of study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior immunosuppressive therapy with ATG (horse of rabbit) or any other lymphocyte&#xD;
             depleting agent (i.e., alemtuzumab)&#xD;
&#xD;
          2. Eligibility to a sibling allogeneic stem cell transplantation&#xD;
&#xD;
          3. Evidence of a myelodysplastic syndrome, defined by the presence of myelodysplastic&#xD;
             features, excess of blasts or karyotypic abnormalities typical of MDS (according to&#xD;
             revised WHO 2008 criteria) [30],, as well as other primitive marrow disease. Patients&#xD;
             with diagnosis of AA with cytogenetic abnormalities which are recurrent in MDS&#xD;
             (according to revised WHO 2008 criteria) [30] should be included in this category, and&#xD;
             are not eligible for the study; patients with del(20q), +8 and -Y are not included in&#xD;
             this category, and thus are eligible for this study. The list of karyotypic&#xD;
             abnormalities which qualifies for the diagnosis of MDS are listed in the Appendix.&#xD;
&#xD;
          4. History or clinical suspect of constitutional aplastic anemia (i.e. Fanconi Anemia&#xD;
             with positive DEB/MMC test or Dyskeratosis Congenita)&#xD;
&#xD;
          5. History of malignant tumors with active disease within 5 years from enrollment, and/or&#xD;
             previous chemo-radiotherapy&#xD;
&#xD;
          6. Previous history of stem cell transplantation&#xD;
&#xD;
          7. Treatment with cyclosporin A unless&#xD;
&#xD;
               -  &lt;4 weeks of cyclosporin A treatment before enrolement and&#xD;
&#xD;
               -  wash out period of 2 weeks before enrollment&#xD;
&#xD;
          8. CMV viremia, as defined by positive PCR or pp65 test&#xD;
&#xD;
          9. WHO performance status ≥3&#xD;
&#xD;
         10. Pregnant or breast feeding patients&#xD;
&#xD;
         11. Patients with hepatic, renal or cardiac failure, or any other life- threatening&#xD;
             concurrent disease&#xD;
&#xD;
         12. Patients with HIV infection&#xD;
&#xD;
         13. Patients without social health care assistance&#xD;
&#xD;
         14. Participation in another clinical trial within 1 month before the start of this trial&#xD;
&#xD;
         15. Patients and/or female partners of male patients not using highly effective method of&#xD;
             birth control i.e. intrauterine device (IUD), hormonal (oral pill, injection,&#xD;
             implants), tubal ligation or partner's vasectomy&#xD;
&#xD;
         16. subjects with known hypersensitivity to any of the component medications&#xD;
&#xD;
        The presence of a Paroxysmal Nocturnal Hemoglobinuria clone is not an exclusion criterion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Risitano, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federico II Medical School, Haematology Division, Napels</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Regis Peffault de Latour, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Louis Hospital, Haematology Division, Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut-Lévèque</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pontchaillou Hospital</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto G. Gaslini children's Hospital</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Martino Hospital</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS ca Granda Ospedale</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>'Federico II' Medical School</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Sapienza University Hospital</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMCU</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias I Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia - Hospital Duran i Reynals</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donostia Hospital</name>
      <address>
        <city>San Sebastian</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zürich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>https://www.ebmt.org/research/studies/race-prospective-randomized-multicenter-study-comparing-horse-antithymocyte</url>
    <description>RACE</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 6, 2014</study_first_submitted>
  <study_first_submitted_qc>March 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2014</study_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aplastic Anaemia</keyword>
  <keyword>Eltrombopag</keyword>
  <keyword>HATG</keyword>
  <keyword>ATGAM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

